Outcome of the Japanese Immune Tolerance Induction (ITI) Registry and Predictors of Successful ITI

被引：0

作者：

Nogami, Keiji ^{[1
]}

Taki, Masashi ^{[2
]}

Matsushita, Tadashi ^{[3
]}

Ohga, Shouichi ^{[4
]}

Hanabusa, Hideji ^{[5
]}

Oka, Toshiaki ^{[6
]}

Horikoshi, Yasuo ^{[7
]}

Amano, Kagehiro ^{[8
]}

Shima, Midori ^{[1
]}

机构：

[1] Nara Med Univ, Dept Pediat, Kashihara, Nara 634, Japan

[2] St Marianna Univ, Sch Med, Dept Pediat, Kawasaki, Kanagawa, Japan

[3] Nagoya Univ Hosp, Dept Transfus Med, Nagoya, Aichi, Japan

[4] Yamaguchi Univ, Dept Pediat, Ube, Yamaguchi 755, Japan

[5] Ogikubo Hosp, Dept Hemalot, Tokyo, Japan

[6] Sapporo Tokushukai Hosp, Dept Pediat, Sapporo, Hokkaido, Japan

[7] Shizuoka Children Hosp, Dept Hematol Oncol, Shizuoka, Japan

[8] Tokyo Med Univ, Dept Lab Med, Tokyo 1608402, Japan

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[31] Immune Tolerance Induction (ITI) with a Plasma-Derived Factor VIII for Patients with Hemophilia a and Inhibitors: A Retrospective Study
Escobar, Miguel A.
Shaffer, Linda
Holguin, Mark
McCavit, Timothy
Rajan, Sandeep K.
Amega, Novinyo
BLOOD, 2019, 134
[32] IMMUNE TOLERANCE INDUCTION (ITI) IN CHILDREN WITH HAEMOPHILIA A WITH INHIBITOR: IN REGION VIII-BUENOS AIRES- ARGENTINA
Martinez, M. S.
Sliba, G.
Batistelli, S.
HAEMOPHILIA, 2020, 26 : 105 - 105
[33] A low-dose immune tolerance induction (ITI) protocol incorporating immunosuppressive agents in haemophilia A children with high-titre factor VIII inhibitor and poor-ITI prognostic risk
Li, Zekun
Chen, Zhenping
Cheng, Xiaoling
Liu, Guoqing
Wu, Xinyi
Li, Gang
Zhen, Yingzi
Cai, Siyu
Poon, Man-Chiu
Wu, Runhui
HAEMOPHILIA, 2021, 27 (04) : E469 - E472
[34] Real-world data of immune tolerance induction (ITI) using recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with severe hemophilia A with inhibitors at high risk for ITI failure
Carcao, M.
Shapiro, A.
Hwang, N.
Pipe, S.
Ahuja, S.
Lieuw, K.
Staber, J.
Belletrutti, M.
Sun, H.
Ding, H.
Wang, M.
Price, V.
Steele, M.
Tsao, E.
Feng, J.
Al-Khateeb, Z.
Dumont, J.
Jain, N.
HAEMOPHILIA, 2019, 25 : 15 - 16
[35] Did rituximab (ANTI-CD20) influence the outcome of late Immune Tolerance Induction (ITI) in an adult with severe hemophilia A (HA) and highresponder inhibitor?
Faradji, A.
Grunebaum, L.
Desprez, D.
Goldbarg, V
Lavigne-Lissalde, G.
Dory, A.
Cecile, Gerout A.
Chilintseva-Natorov, N.
Eischen, A.
Feugeas, O.
Karcher, P.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 469 - 470
[36] Factor VIII gene (F8) mutations as a predictor of outcome in immune tolerance induction (ITI) in hemophilia A patients with high-responding inhibitors
Coppola, A.
Margaglione, M.
Santagostino, E.
Rocino, A.
Scaraggi, F.
Tagliaferri, A.
Castaman, G.
Messina, M.
Mancuso, M. E.
Iorio, A.
Schinco, P.
Zanon, E.
Musso, R.
Mancuso, G.
Di Minno, G.
Mannucci, P.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 191 - 192
[37] rFIXFc for Immune Tolerance Induction in a Severe Hemophilia B Patient with an Inhibitor and Prior History of ITI Related Nephrotic Syndrome
Malec, Lynn
Abshire, Thomas
Jobe, Shawn
White, Gilbert
HAEMOPHILIA, 2018, 24 (04) : E294 - E296
[38] Successful immune tolerance induction rescue (ITI-R) with simoctocog alfa (rHFVIII) in hemophilia A patients and high-titer inhibitors: Three case reports
Zanon, E.
Pasca, S.
Marino, R.
Ricca, I.
Pollio, B.
HAEMOPHILIA, 2019, 25 : 84 - 85
[39] Long-term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma-derived FVIII/VWF product: the long-term ITI study
Jimenez-Yuste, V.
Oldenburg, J.
Rangarajan, S.
Peiro-Jordan, R.
Santagostino, E.
HAEMOPHILIA, 2016, 22 (06) : 859 - 865
[40] IMPAIRED TOLERANCE IN THE INTERNATIONAL IMMUNE TOLERANCE INDUCTION STUDY (I-ITI STUDY) IS RELATED TO THE PRESENCE OF VERY LOW-TITER INHIBITORS
Valke, L. L.
Hay, C. R.
DiMichele, D. M.
Polenewen, R.
Meijer, D.
Verhagen, M. J.
Schols, S. E.
Van Heerde, W. L.
HAEMOPHILIA, 2023, 29 : 34 - 35

← 1 2 3 4 5 →